CLAIM AMENDMENTS UNDER THE PROVISION OF 37 CFR § 1.121(c)(1)(i)

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (canceled) A dual-specificity antibody, or antigen-binding portion thereof, that specifically binds interleukin-1α and interleukin-1β, wherein said dual-specificity antibody is not a fully mouse antibody.

2. (canceled) The dual-specificity antibody of claim 1, or antigen-binding portion thereof, which binds interleukin-1α with a k_{off} rate constant of $0.1s^{-1}$ or less, as determined by surface plasmon resonance, or which inhibits the activity of interleukin-1α with an IC_{50} of 1×10^{-5} M or less.

3. (canceled) The dual-specificity antibody of claim 1, or antigen-binding portion thereof, which binds interleukin-1β with a k_{off} rate constant of $0.1s^{-1}$ or less, as determined by surface plasmon resonance, or which inhibits the activity of interleukin-1β with an IC_{50} of 1×10^{-5} M or less.

4. (previously presented) A method of obtaining a dual-specificity antibody that specifically binds interleukin-1α and interleukin-1β, the method comprising:
providing an antigen, wherein the antigen comprises the amino acid sequence TKGGQDITDFQILENQ (SEQ ID NO: 3);
exposing an antibody repertoire to the antigen; and
selecting from the repertoire an antibody that specifically binds IL-1α and IL-1β to thereby obtain the dual specificity antibody, wherein said dual-specificity antibody is not a fully mouse antibody.

5. (withdrawn) The method of claim 4, wherein the antigen is designed based on a contiguous topological area of identity between IL-1α and IL-1β.

6. (withdrawn) The method of claim 5, wherein the antigen comprises the amino acid sequence NEAQNITDF (SEQ ID NO: 1) or dNdEdAdQNITDF.

7. (withdrawn) The method of claim 4, wherein the antigen is designed based on structurally mimicking a loop of a common fold of IL-1α and IL-1β.

8. (withdrawn) The method of claim 7, wherein the antigen is a cyclic peptide comprising the amino acid sequence Cyclo-MAFLRANQNNGKISVAL(PG) (SEQ ID NO: 2).

9. (canceled) The method of claim 4, wherein the antigen is designed based on splicing together overlapping portions of IL-1α and IL-1β to create a hybrid molecule.

10. (canceled) The method of claim 9, wherein the antigen comprises the amino acid sequence TKGGQDITDFQILENQ (SEQ ID NO: 3).

11. (withdrawn) The method of claim 4, wherein the antigen comprises the amino acid sequence